Rajan Remya, Cherian Kripa E, Kapoor Nitin, Paul Thomas V
Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, Tamil Nadu, India.
Indian J Endocrinol Metab. 2020 May-Jun;24(3):237-243. doi: 10.4103/ijem.IJEM_147_20. Epub 2020 Jun 30.
Areal bone mineral density (aBMD) is currently the gold standard for the diagnosis of osteoporosis, however, it has its own pitfalls. Trabecular bone score (TBS), a novel tool in the evaluation of osteoporosis is an indirect indicator of bone microarchitecture. It is a textural index that evaluates pixel gray-level variations in the lumbar spine DXA (dual energy X-ray absorptiometry) image. Both cross-sectional and longitudinal studies have demonstrated that TBS may independently predict fragility fractures. TBS can also be used to adjust FRAX probabilities of fracture, though data available till date doesn't support any additional benefit. TBS also shows an improving trend with anti-osteoporotic treatment; however, the least significant change (LSC) is high that it takes more than 2 years for the change to manifest. TBS is also used in the evaluation of bone strength in cases of secondary osteoporosis. Though TBS predicts fracture risk independently in both genders, with the currently available data, it cannot be recommended as a standalone tool for decision regarding treatment of osteoporosis. TBS can be used as a tool to complement BMD in assessment of bone health. Additional studies are needed to assess its utility in clinical practice.
面积骨密度(aBMD)是目前诊断骨质疏松症的金标准,然而,它有其自身的缺陷。小梁骨评分(TBS)是评估骨质疏松症的一种新工具,是骨微结构的间接指标。它是一种纹理指数,用于评估腰椎双能X线吸收法(DXA)图像中的像素灰度变化。横断面研究和纵向研究均表明,TBS可独立预测脆性骨折。TBS还可用于调整骨折风险评估工具(FRAX)的骨折概率,尽管迄今为止的现有数据不支持其有任何额外益处。TBS在抗骨质疏松治疗中也呈改善趋势;然而,最小有意义变化(LSC)较高,变化显现需要两年多时间。TBS还用于评估继发性骨质疏松症患者的骨强度。尽管TBS在男女中均可独立预测骨折风险,但根据目前可用数据,它不能作为决定骨质疏松症治疗的独立工具推荐使用。在评估骨骼健康时,TBS可作为补充骨密度的工具。需要更多研究来评估其在临床实践中的效用。